Epilepsy

Purpose of Study:  To evaluate the effects of an investigational drug on total partial seizure frequency in adolescent and adult patients with refractory partial onset seizures maintained on a maximum of three stable antiepileptic medications.

Inclusion Criteria:

• Age 12-80 years
• Diagnosed with Epilepsy supported by clinical history, EEG and CT/MRI
• Non-controlled partial seizures despite having been treated with at least two different antiepileptic drugs for at least two years
• Must experience at least 6 seizures during a 56-day baseline with no 21 day seizure free period
• Current treatment with a maximum of three approved antiepileptic drugs and taking a stable dose of the same AED(s) for one month prior to screening
• If using a vagal nerve stimulator (VNS), it must have been implanted for at least six months prior to randomization

Exclusion Criteria:

• Diagnosis of major active psychiatric disease and/or attempted suicide within the previous 10 years
• History of drug and/or alcohol abuse
• Progressive central nervous system (CNS) disease, including degenerative CNS disease and progressive tumors
• Frequent need of rescue benzodiazepines (more than once a month)
• Patients with a known hypersensitivity to rufinamide, triazole derivatives, or to any excipients used in the formulation

If you qualify, all study related care is provided at no charge including:

• Study visits and study related procedures/tests
• Laboratory tests
• Investigational drug
• Possible reimbursement for time and travel

Inclusion/Exclusion Criteria Must Be Met